Skip to main
ALT

Altimmune (ALT) Stock Forecast & Price Target

Altimmune (ALT) Analyst Ratings

Based on 7 analyst ratings
Strong Buy
Strong Buy 57%
Buy 43%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Altimmune Inc. is strategically positioned to capitalize on the market potential for metabolic dysfunction-associated steatohepatitis (MASH) due to the promising characteristics of its lead candidate, pemvidutide, which offers a dual GLP-1/glucagon mechanism that enhances tolerability and metabolic improvement. Recent industry activity, such as Novo's acquisition of Akero Therapeutics, signals a growing recognition of the need for innovative treatments in the MASH sector, thereby validating pemvidutide’s strategic fit within this evolving landscape. The company's leadership team is enhancing its capabilities ahead of significant clinical milestones, which could further bolster investor confidence and support a broad therapeutic reach in addressing MASH across varying patient stages.

Bears say

The negative outlook on Altimmune's stock is primarily driven by significant clinical development risks associated with pemvidutide, which is still in the early stages of testing and may face challenges in demonstrating efficacy and safety. Additionally, competitive pressures in the biopharmaceutical industry could hamper the company's market entry and commercialization efforts, potentially affecting future revenue generation. Furthermore, ongoing uncertainties related to reimbursement, pricing strategies, and external factors such as the impact of COVID-19 and geopolitical tensions may adversely influence investor confidence and market performance.

Altimmune (ALT) has been analyzed by 7 analysts, with a consensus rating of Strong Buy. 57% of analysts recommend a Strong Buy, 43% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Altimmune and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Altimmune (ALT) Forecast

Analysts have given Altimmune (ALT) a Strong Buy based on their latest research and market trends.

According to 7 analysts, Altimmune (ALT) has a Strong Buy consensus rating as of Dec 30, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $18, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $18, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Altimmune (ALT)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.